As we are approaching the end of another year that failed to see marijuana legalized on the federal level, there’s a bit of blame-shifting going on between the leading parties.
According to a GOP congressman, Democrats are responsible for Congress’ inability to pass a federal marijuana legalization bill, Marijuana Moment writes.
What Happened
Rep. Matt Gaetz (R-FL) said last week during an episode of his Firebrand podcast that “Democrats, particularly the Congressional Black Caucus,” are to be blamed for cannabis still being a Schedule I drug — considered to be more dangerous than opioids, while offering no medical benefits.
He’s been critical of Democrats who’ve insisted that legalization measures contain specific equity provisions poised to address the consequences of the War on Drugs, emphasizing that they might be unnecessary and only holding up the adoption of long-anticipated and bipartisan-supported federal cannabis reform.
Why It Matters
Gaetz was one of few House Republicans who voted in favor of the MORE act last year, a piece of legislation that could effectively decriminalize marijuana on a federal level. On the other hand, nearly every Democrat in the House voted to legalize cannabis, thus leading the charge on legalization.
The congressmen also shared his thoughts on the history of drug criminalization and the congressional response to the opioid epidemic, arguing that Democrats have been “fixated on opioids” in the 117th Congress —introducing numerous pieces of legislation aimed at mitigating the crisis— but they “can’t move the marijuana bill successfully.”
However, the latest breakthrough in the field came from the two Republican lawmakers who recently introduced new legislation in the House of Senate poised to further streamline research of Schedule I drugs like marijuana and psilocybin.
What’s Next
Halt All Lethal Trafficking of (HALT) Fentanyl Act is set to limit trafficking of powerful opioid. Filed by Sen. Bill Cassidy (R-LA) and Rep. Morgan Griffith (R-VA), the companion bills also include provisions to streamline the research process for all Schedule I drugs under the Controlled Substances Act, with the strict category including psychedelics like LSD, mescaline, and MDMA, besides cannabis.
Photo: Courtesy of Esteban Lopez on Unsplash
Be the first to comment